Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Invested Capital (2023 - 2025)

Historic Invested Capital for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • BioLineRx's Invested Capital fell 5439.83% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year decrease of 3363.0%. This contributed to the annual value of $4.5 million for FY2024, which is 4241.65% up from last year.
  • BioLineRx's Invested Capital amounted to $4.5 million in Q3 2025, which was down 5439.83% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Invested Capital registered a high of $10.7 million during Q2 2024, and its lowest value of $2.6 million during Q1 2023.
  • Moreover, its 3-year median value for Invested Capital was $4.5 million (2024), whereas its average is $4.9 million.
  • As far as peak fluctuations go, BioLineRx's Invested Capital surged by 24619.88% in 2024, and later tumbled by 5796.73% in 2025.
  • Over the past 3 years, BioLineRx's Invested Capital (Quarter) stood at $3.1 million in 2023, then surged by 42.42% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
  • Its Invested Capital was $4.5 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.7 million in Q1 2025.